+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 100Years
All Genders
ID06133972

Long-term Safety and Tolerability Study of Ianalumab Compared to Placebo in Systemic Lupus Erythematosus Participants Who Completed Prior SIRIUS-SLE Trials

Led by Novartis Pharmaceuticals · Updated on 2026-10-13

550

Participants Needed

164

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the long-term safety and tolerability of ianalumab in adolescents and adults with systemic lupus erythematosus who have previously completed treatment in one of two core SIRIUS-SLE studies. This extension study focuses on participants with moderate-to-severe disease activity and positive anti-nuclear antibodies. The study is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by Novartis Pharmaceuticals. The study involves three treatment periods over up to 7 years a 3-year double-blind phase where participants receive ianalumab subcutaneously either monthly or quarterly, or a monthly placebo followed by a 2-year period assessing safety and efficacy of treatment withdrawal and open-label monthly ianalumab and finally, an open-label safety monitoring period lasting up to 2 years. Participants receive the treatments subcutaneously as scheduled during each period. Participants will be closely monitored throughout the study, with assessments covering adverse events, disease activity responses, damage indices, corticosteroid use, and antibody levels. The primary measure is the number of treatment-emergent adverse events or serious adverse events up to about 324 weeks. Regular evaluations include clinical assessments, laboratory tests, and serum measurements. The total study duration for participants may extend up to 7 years, including long-term safety follow-up.

CONDITIONS

Brief Title

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here